Type 2 Diabetes Clinical Trials in Houston, Texas
18 recruitingHouston, Texas
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Type 2 Diabetes
Eli Lilly and Company55 enrolled51 locationsNCT06739122
Recruiting
Not Applicable
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University420 enrolled7 locationsNCT06906640
Recruiting
Phase 2
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
Type 2 DiabetesCortisol Excess
Sparrow Pharmaceuticals1,500 enrolled60 locationsNCT07296484
Recruiting
Phase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
Type 2 Diabetes
Biomea Fusion Inc.60 enrolled17 locationsNCT07502508
Recruiting
Not Applicable
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Insulet Corporation200 enrolled12 locationsNCT07579702
Recruiting
Phase 3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
ObesityType 2 Diabetes
Novo Nordisk A/S2,500 enrolled303 locationsNCT07564414
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled61 locationsNCT07351058
Recruiting
Phase 2
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Type 2 Diabetes
Eli Lilly and Company240 enrolled60 locationsNCT06897475
Recruiting
Phase 2
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Type 2 Diabetes
Biomea Fusion Inc.60 enrolled16 locationsNCT07502495
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Prokidney685 enrolled95 locationsNCT05099770
Recruiting
Phase 3
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Type 2 Diabetes (T2DM)LipidemiaMetabolic Syndrome (MetS)
NewAmsterdam Pharma300 enrolled20 locationsNCT07219602
Recruiting
Phase 2
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
ObesityWeight LossObese+1 more
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics50 enrolled17 locationsNCT07400588
Recruiting
Not Applicable
Arginine Metabolism in Youth With Type 2 Diabetes
Type 2 Diabetes
Baylor College of Medicine30 enrolled1 locationNCT05477134
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472
Recruiting
Not Applicable
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Diabetes Mellitus, Type 2DiabetesType 2 Diabetes+2 more
Endogenex, Inc.264 enrolled45 locationsNCT06267391
Recruiting
Not Applicable
CGM for Management of Type 2 Diabetes in Pregnancy
PregnancyType 2 Diabetes Mellitus (T2DM)
University of Alabama at Birmingham564 enrolled7 locationsNCT06628453
Recruiting
Not Applicable
Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents
Obesity and Type 2 Diabetes
Baylor College of Medicine40 enrolled1 locationNCT06943001